PARP inhibitors in BRCA mutation-associated ovarian cancer
- PMID: 25481790
- DOI: 10.1016/S1470-2045(14)71172-6
PARP inhibitors in BRCA mutation-associated ovarian cancer
Comment on
-
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical